It was a relatively quiet week in the San Diego life sciences community, but local companies and organizations continue working away. Here’s a look at some recent developments, including companies moving their lead drug candidates into Phase 2 trials, new R&D partnerships, and a reminder to nominate your favorite young’un for a Biocom Catalyst award.

—MEI Pharma, a late-stage cancer drug developer, presented updated data from a Phase 1b study of its lead drug candidate, ME-401, which is designed to inhibit a molecular pathway called PI3K delta. The company said it recorded an 83 percent response rate among the 71 patients… Read more »